Athenex, Inc. (ATNX)

Trade ATNX now with
12/11/2018 7:07:12 AM Athenex Announces Positive Second Cohort Results Of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial In Gastric Cancer
11/29/2018 7:12:24 AM Athenex Enters Agreement With PharmaEssentia To License Rights To Develop, Commercialize Oradoxel
11/14/2018 7:05:05 AM Athenex Q3 Net Loss Attributable To Athenex $46.2 Mln Or $0.70/Shr Vs Loss Of $23.3 Mln Or $0.41/Shr Last Year
10/29/2018 7:03:19 AM Athenex Reports FDA Allowance Of Investigational NDA Of Eribulin ORA To Begin Clinical Trials
10/22/2018 7:18:58 AM Athenex Presents Encouraging Clinical Trial Efficacy And Safety Results Of Oraxol In Metastatic Breast Cancer
10/16/2018 8:08:33 AM Athenex To Present Positive Data Of Oraxol Clinical Trial In Breast Cancer At The ESMO 2018 Congress
10/15/2018 7:07:25 AM Athenex, Xiangxue Life Sciences Announce Preliminary Results Of TAEST Showed Encouraging Positive Clinical Signals
9/5/2018 7:09:43 AM Athenex Says DSMB Congratulated On Rapid Patient Recruitment, Promising Results Achieved In Oraxol 001 Phase III Trial
8/20/2018 8:03:16 AM Athenex Appoints Randoll Sze As CFO
8/14/2018 7:11:50 AM Athenex Q2 Revenue $11.6 Mln Vs $4.6 Mln Last Year
8/9/2018 9:05:24 AM Athenex Gets FDA Clearance To Import Potassium Chloride Injection Concentrate To Address U.S. Drug Shortage
7/2/2018 6:31:45 AM Athenex Reports Collaboration With Xiangxue Pharmaceutical Expands Portfolio In To TCR-T Immunotherapy
6/15/2018 7:04:22 AM Athenex Appoints Benson Tsang To Board Of Directors, Effective July 1
6/14/2018 3:02:04 AM This Day That Year: Athenex
6/4/2018 8:08:57 AM Athenex Names Christina Wang As VP Of Clinical Operations And Corporate Development, Asia Pacific
5/14/2018 7:11:09 AM Athenex Q1 Net Loss $7.3 Mln Vs Net Loss $41.0 Mln Year Ago
4/30/2018 6:31:37 AM Athenex Announces Transition Of James Zukin From Board To An Advisory Role
4/19/2018 8:07:47 AM Athenex Gets FDA Orphan Drug Designation For Oraxol For Angiosarcoma
4/9/2018 8:04:33 AM Cerecor Appoints Simon Pedder To Board Of Directors
3/26/2018 7:17:00 AM Athenex Q4 Net Loss Attributable $28.28 Mln Vs Loss $40.05 Mln Last Year